NCT00334438View on ClinicalTrials.gov

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2011

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

250mg/m2, IV, Days 1 and 8

DRUG

bortezomib

dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8

RADIATION

Indium 111 ibritumomab tiuxetan

5cmCi; IV day 1

Trial Locations (2)

07601

Hackensack University Medical Center Cancer Center, Hackensack

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00334438 - Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter